O	0	7	Results
O	8	10	of
O	11	14	the
O	15	22	CONFIRM
O	23	28	phase
O	29	32	III
O	33	38	trial
O	39	48	comparing
B-control	49	60	fulvestrant
I-control	61	64	250
I-control	65	67	mg
O	68	72	with
B-intervention	73	84	fulvestrant
I-intervention	85	88	500
I-intervention	89	91	mg
O	92	94	in
O	95	109	postmenopausal
O	110	115	women
O	116	120	with
O	121	129	estrogen
O	130	138	receptor
O	138	139	-
O	139	147	positive
O	148	156	advanced
O	157	163	breast
O	164	170	cancer
O	170	171	.

O	172	174	We
O	175	183	compared
O	184	195	fulvestrant
O	196	199	500
O	200	202	mg
O	203	210	regimen
O	211	215	with
O	216	219	the
O	220	228	approved
O	229	233	dose
O	234	236	of
O	237	248	fulvestrant
O	249	252	250
O	253	255	mg
O	256	259	per
O	260	265	month
O	266	269	for
O	270	279	treatment
O	280	282	of
B-eligibility	283	297	postmenopausal
I-eligibility	298	303	women
I-eligibility	304	308	with
I-eligibility	309	317	estrogen
I-eligibility	318	326	receptor
I-eligibility	326	327	-
I-eligibility	327	335	positive
I-eligibility	336	344	advanced
I-eligibility	345	351	breast
I-eligibility	352	358	cancer
I-eligibility	359	362	who
I-eligibility	363	374	experienced
I-eligibility	375	386	progression
I-eligibility	387	392	after
I-eligibility	393	398	prior
I-eligibility	399	408	endocrine
I-eligibility	409	416	therapy
O	416	417	.

O	418	428	Comparison
O	429	431	of
O	432	440	Faslodex
O	441	443	in
O	444	453	Recurrent
O	454	456	or
O	457	467	Metastatic
O	468	474	Breast
O	475	481	Cancer
O	482	483	(
O	483	490	CONFIRM
O	490	491	)
O	492	494	is
O	495	496	a
O	497	503	double
O	503	504	-
O	504	509	blind
O	509	510	,
O	511	519	parallel
O	519	520	-
O	520	525	group
O	525	526	,
O	527	538	multicenter
O	538	539	,
O	540	545	phase
O	546	549	III
O	550	555	study
O	555	556	.

O	557	565	Patients
O	566	570	were
O	571	579	randomly
O	580	588	assigned
O	589	591	to
O	592	603	fulvestrant
O	604	607	500
O	608	610	mg
O	611	612	(
O	612	615	500
O	616	618	mg
O	619	634	intramuscularly
O	635	636	[
O	636	638	IM
O	638	639	]
O	640	642	on
O	643	646	day
O	647	648	0
O	648	649	,
O	650	654	then
O	655	658	500
O	659	661	mg
O	662	664	IM
O	665	667	on
O	668	672	days
O	673	675	14
O	676	679	and
O	680	682	28
O	683	686	and
O	687	692	every
O	693	695	28
O	696	700	days
O	701	711	thereafter
O	711	712	)
O	713	715	or
O	716	719	250
O	720	722	mg
O	723	728	every
O	729	731	28
O	732	736	days
O	736	737	.

O	738	745	Primary
O	746	749	end
O	750	755	point
O	756	759	was
B-outcome-Measure	760	771	progression
I-outcome-Measure	771	772	-
I-outcome-Measure	772	776	free
I-outcome-Measure	777	785	survival
I-outcome-Measure	786	787	(
I-outcome-Measure	787	790	PFS
I-outcome-Measure	790	791	)
O	791	792	.

O	793	802	Secondary
O	803	806	end
O	807	813	points
O	814	822	included
B-outcome-Measure	823	832	objective
I-outcome-Measure	833	841	response
I-outcome-Measure	842	846	rate
O	846	847	,
B-outcome-Measure	848	856	clinical
I-outcome-Measure	857	864	benefit
I-outcome-Measure	865	869	rate
I-outcome-Measure	870	871	(
I-outcome-Measure	871	874	CBR
I-outcome-Measure	874	875	)
O	875	876	,
B-outcome-Measure	877	885	duration
I-outcome-Measure	886	888	of
I-outcome-Measure	889	897	clinical
I-outcome-Measure	898	905	benefit
I-outcome-Measure	906	907	(
I-outcome-Measure	907	911	DoCB
I-outcome-Measure	911	912	)
O	912	913	,
B-outcome-Measure	914	921	overall
I-outcome-Measure	922	930	survival
I-outcome-Measure	931	932	(
I-outcome-Measure	932	934	OS
I-outcome-Measure	934	935	)
O	935	936	,
O	937	940	and
B-outcome-Measure	941	948	quality
I-outcome-Measure	949	951	of
I-outcome-Measure	952	956	life
I-outcome-Measure	957	958	(
I-outcome-Measure	958	961	QOL
I-outcome-Measure	961	962	)
O	962	963	.

B-outcome	964	967	PFS
O	968	971	was
O	972	985	significantly
O	986	992	longer
O	993	996	for
O	997	1008	fulvestrant
O	1009	1012	500
O	1013	1015	mg
O	1016	1017	(
O	1017	1018	n
O	1019	1020	=
B-intervention-participants	1021	1024	362
O	1024	1025	)
O	1026	1030	than
O	1031	1034	250
O	1035	1037	mg
O	1038	1039	(
O	1039	1040	n
O	1041	1042	=
B-control-participants	1043	1046	374
O	1046	1047	)
O	1048	1049	(
O	1049	1055	hazard
O	1056	1061	ratio
O	1062	1063	[
O	1063	1065	HR
O	1065	1066	]
O	1067	1068	=
O	1069	1070	0
O	1070	1071	.
O	1071	1073	80
O	1073	1074	;
O	1075	1077	95
O	1077	1078	%
O	1079	1081	CI
O	1081	1082	,
O	1083	1084	0
O	1084	1085	.
O	1085	1087	68
O	1088	1090	to
O	1091	1092	0
O	1092	1093	.
O	1093	1095	94
O	1095	1096	;
O	1097	1098	P
O	1099	1100	=
O	1101	1102	.
O	1102	1105	006
O	1105	1106	)
O	1106	1107	,
O	1108	1121	corresponding
O	1122	1124	to
O	1125	1126	a
O	1127	1129	20
O	1129	1130	%
O	1131	1140	reduction
O	1141	1143	in
O	1144	1148	risk
O	1149	1151	of
O	1152	1163	progression
O	1163	1164	.

B-outcome	1165	1174	Objective
I-outcome	1175	1183	response
I-outcome	1184	1188	rate
O	1189	1192	was
O	1193	1200	similar
O	1201	1204	for
O	1205	1216	fulvestrant
O	1217	1220	500
O	1221	1223	mg
O	1224	1227	and
O	1228	1231	250
O	1232	1234	mg
O	1235	1236	(
B-iv-bin-percent	1236	1237	9
I-iv-bin-percent	1237	1238	.
I-iv-bin-percent	1238	1239	1
I-iv-bin-percent	1239	1240	%
O	1241	1242	v
B-cv-bin-percent	1243	1245	10
I-cv-bin-percent	1245	1246	.
I-cv-bin-percent	1246	1247	2
I-cv-bin-percent	1247	1248	%
O	1248	1249	,
O	1250	1262	respectively
O	1262	1263	)
O	1263	1264	.

B-outcome	1265	1268	CBR
O	1269	1272	was
B-iv-bin-percent	1273	1275	45
I-iv-bin-percent	1275	1276	.
I-iv-bin-percent	1276	1277	6
I-iv-bin-percent	1277	1278	%
O	1279	1282	for
O	1283	1294	fulvestrant
O	1295	1298	500
O	1299	1301	mg
O	1302	1305	and
B-cv-bin-percent	1306	1308	39
I-cv-bin-percent	1308	1309	.
I-cv-bin-percent	1309	1310	6
I-cv-bin-percent	1310	1311	%
O	1312	1315	for
O	1316	1327	fulvestrant
O	1328	1331	250
O	1332	1334	mg
O	1334	1335	.

B-outcome	1336	1340	DoCB
O	1341	1344	and
B-outcome	1345	1347	OS
O	1348	1352	were
B-iv-cont-median	1353	1355	16
I-iv-cont-median	1355	1356	.
I-iv-cont-median	1356	1357	6
O	1358	1361	and
B-cv-cont-median	1362	1364	25
I-cv-cont-median	1364	1365	.
I-cv-cont-median	1365	1366	1
I-cv-cont-median	1367	1373	months
O	1373	1374	,
O	1375	1387	respectively
O	1387	1388	,
O	1389	1392	for
O	1393	1396	the
O	1397	1400	500
O	1400	1401	-
O	1401	1403	mg
O	1404	1409	group
O	1409	1410	,
O	1411	1418	whereas
B-outcome	1419	1423	DoCB
O	1424	1427	and
B-outcome	1428	1430	OS
O	1431	1435	were
B-cv-cont-median	1436	1438	13
I-cv-cont-median	1438	1439	.
I-cv-cont-median	1439	1440	9
O	1441	1444	and
B-cv-cont-median	1445	1447	22
I-cv-cont-median	1447	1448	.
I-cv-cont-median	1448	1449	8
I-cv-cont-median	1450	1456	months
O	1456	1457	,
O	1458	1470	respectively
O	1470	1471	,
O	1472	1474	in
O	1475	1478	the
O	1479	1482	250
O	1482	1483	-
O	1483	1485	mg
O	1486	1491	group
O	1491	1492	.

O	1493	1504	Fulvestrant
O	1505	1508	500
O	1509	1511	mg
O	1512	1515	was
B-outcome	1516	1520	well
I-outcome	1521	1530	tolerated
O	1531	1535	with
O	1536	1538	no
O	1539	1543	dose
O	1543	1544	-
O	1544	1553	dependent
B-outcome	1554	1561	adverse
I-outcome	1562	1568	events
O	1568	1569	.

B-outcome	1570	1573	QOL
O	1574	1577	was
O	1578	1585	similar
O	1586	1589	for
O	1590	1594	both
O	1595	1599	arms
O	1599	1600	.

O	1601	1612	Fulvestrant
O	1613	1616	500
O	1617	1619	mg
O	1620	1623	was
O	1624	1634	associated
O	1635	1639	with
O	1640	1641	a
O	1642	1655	statistically
O	1656	1667	significant
O	1668	1676	increase
O	1677	1679	in
O	1680	1683	PFS
O	1684	1687	and
O	1688	1691	not
O	1692	1702	associated
O	1703	1707	with
O	1708	1717	increased
O	1718	1726	toxicity
O	1726	1727	,
O	1728	1741	corresponding
O	1742	1744	to
O	1745	1746	a
O	1747	1757	clinically
O	1758	1768	meaningful
O	1769	1780	improvement
O	1781	1783	in
O	1784	1791	benefit
O	1792	1798	versus
O	1799	1803	risk
O	1804	1812	compared
O	1813	1817	with
O	1818	1829	fulvestrant
O	1830	1833	250
O	1834	1836	mg
O	1836	1837	.
